SWTX springworkstx.com Net earnings per share growth forecast for next year

Corporate company logo of SpringWorks Therapeutics, Inc (SWTX)

SpringWorks Therapeutics (SWTX) relies on the development of precision therapy for rare neoplasms, which has stabilized cash flows following the launch of its primary drug. The consensus earnings per share (EPS) forecast visualizes the future revenue trajectory, with the value of 3.40 characterizing this level. High authority in oncology and minimal geopolitical risks within the US confirm the reliability of the company's investment profile.

SWTX: SpringWorks Therapeutics Inc. Net earnings per one share growth forecast for next year 07/04/2022 - 07/12/2025

Financial and market metric breakdowns for springworkstx.com (SWTX)

- share price and consensus valuation forecast:
Stock Price SpringWorks|SWTX - Analyst Consensus Forecast
- market capitalization data:
Market Value SpringWorks Therapeutics|SWTX - Value Adjusted for Debt and Cash
- company book value details:
Book Value per Share SpringWorks Therapeutics|SWTX - Book Value of Business|Market Capitalization to Book Value Ratio springworkstx.com|SWTX - Company Assets
- company total debt and liquidity indicators:
Total Debt to Equity Ratio SpringWorks Therapeutics|SWTX - Long-Term Loans to Capital Ratio|Short-Term Debt to Capital SpringWorks Therapeutics, Inc.|SWTX - Company Cumulative Debt|Debts to Book Capitalization SpringWorks Therapeutics|SWTX - Company Long-Term Indebtedness|Company Current Liabilities SpringWorks Therapeutics|Quick Liquidity Indicator springworkstx.com
- earnings and valuation multiples information:
SWTX - Profit After Payment of Taxes|Projected Future Earnings SpringWorks Therapeutics|SWTX - Company Value to Net Income|Forward P/E Multiple SpringWorks Therapeutics|SWTX - Price to Earnings Adjusted for Growth Rate|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization SpringWorks Therapeutics|SWTX - Income before deduction of interest, taxes and amortization|Net earnings per share (EPS TTM) SpringWorks Therapeutics|SWTX - Net earnings per share (EPS TTM)|Year-over-year earnings per share growth for the last twelve months springworkstx.com|SWTX - Earnings per share trend in current year|Expected earnings per share growth for next year SpringWorks Therapeutics
Fundamental company analysis:SpringWorks, SWTX
Brand item of springworkstx.com

The commercialization of Ogsiveo and the progress of mirdametinib drive the growth potential of SpringWorks Therapeutics (SWTX), which is directly reflected in the expected EPS growth for the coming year. This metric aggregates analyst earnings forecasts, allowing investors to identify the inflow of institutional capital into the asset prior to the release of official reports and avoid allocating funds to overvalued securities.

Competing companies

GMAB (Genmab US) - Earnings growth forecast for next year|Earnings growth forecast for next year Exelixis Inc.|Net earnings per share growth forecast for next year Nuvalent, Inc. (NUVL)|KYMR (kymeratx.com) - Expected earnings per share trend next year|Earnings growth forecast for next year IDYA (IDEAYA Biosciences, Inc.)|Net earnings per one share growth forecast for next year Enliven Therapeutics Inc|ORIC Pharma - Earnings growth forecast for next year|Expected net earnings per share growth next year Relay Corp|NRIX (Nurix Therapeutics) - Expected earnings per share growth for next year|TYRA: Projected earnings per share increase next year|VSTM (Verastem) - Earnings growth forecast for next year|Expected net earnings per share growth next year Monte Rosa Therapeutics Inc GLUE|Earnings growth forecast for next year CGEM|Immuneering Corp. - Projected earnings per share growth rate for next year|C4 Therapeutics, Inc. - Expected earnings per share growth for next year|Expected earnings per share trend next year BDTX|RPTX: Expected earnings per share growth for next year|PMV Pharmaceuticals Inc. - Projected earnings per share increase next year|KPTI: Earnings growth forecast for next year|Propanc Biopharma - Expected earnings per share trend next year|BGMS (Bio Green Med Solution Inc) - Earnings growth forecast for next year|Expected net earnings per share growth next year Aadi Bio AADI|Net earnings per share growth forecast for next year Aileron Therapeutics (ALRN)|BPMC (blueprintmedicines.com) - Expected earnings per share trend next year|Earnings growth forecast for next year GLYC (GlycoMimetics)